Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.19

-1.4%

Dec 30 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (10679)	2/27/2004 10:44:56 AM
From: Gulo	Read Replies (1) of 52153

I haven't posted much here, except to ask for opinions on certain companies (ONCY and SYY.TO). I continue that trend by asking for opinions on HBY. Hybridon is working on antisense inhibition of MDM2, with promising results in preclinical work. Is anyone here familiar with other companies working on antisense cancer therapies? biz.yahoo.com "Now that MDM2 has been shown in cell-based models to bind directly to p21 as well as to p53, the antisense approach to MDM2 inhibition is even more attractive," said Dr. Agrawal. "As we have reported previously, our MDM2 antisense drug candidate has potent antitumor effects in combination with radiation or various chemotherapeutic agents in animal models." XIAP antisense may have even more potential: biz.yahoo.com Disclaimer: I bought HBY recently, based on the chart, insider buying and my preliminary assessment of the technology. Antisense therapy is fairly new to me, so comments from more learned threadsters would be appreciated. I suppose I should have asked for opinions before buying, but I have the patience and attention span of a 5-year-old. -g

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next